ReviewClinical interventions in aging2016
Overactive bladder: strategies to ensure treatment compliance and adherence.
Review in Clinical interventions in aging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effects of Digital Interventions on Symptom Improvement and Quality of Life in Patients With Overactive Bladder: Systematic Review and Meta-Analysis.Journal of medical Internet research · 2026Pooled it
- Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2023Pooled it
- Ion Channels as Therapeutic Targets in Overactive Bladder: A Narrative Review of Mechanisms, Translational Evidence, and Current Gaps.Lower urinary tract symptoms · 2026Review
- Article
- The Efficacy of an Active Medicinal Alkaloid, Berbamine, in Reducing Overactive Bladder Symptoms in a Retinyl Acetate-Induced Model.Biomolecules · 2025Article
- Evaluating and understanding combination therapy decision drivers for the treatment of overactive bladder in the United States.The Journal of international medical research · 2022Article
- The Costs and Healthcare Resource Utilization Associated with Anticholinergic Burden in Long-Stay Nursing Home Residents with Overactive Bladder in the US.PharmacoEconomics - open · 2021Article
- Urinary Microbiome: Yin and Yang of the Urinary Tract.Frontiers in cellular and infection microbiology · 2021Review
- Taking OAB seriously: A qualitative evaluation of primary care education on overactive bladder syndrome management.International journal of clinical practice · 2020Article
- Hypnotherapy or medications: a randomized noninferiority trial in urgency urinary incontinent women.American journal of obstetrics and gynecology · 2020Article
- Patient treatment preferences for symptomatic refractory urodynamic idiopathic detrusor overactivity.Urology annalsArticle
- Comparision effects of solifenacin, darifenacin, propiverine on ocular parameters in eyes: A prospective study.International braz j urol : official journal of the Brazilian Society of UrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Overactive bladder is a common, debilitating condition for many patients who may benefit from pharmacological management of their condition. However, adherence to medication in this condition is markedly worse than other chronic medical conditions. This review explores what is known about persistence and the factors which influence medication adherence for overactive bladder, those factors that might be modifiable to improve adherence, and the measures the health care provider can take to optimize adherence to therapy and thereby improve treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.